Wedbush Has Negative Outlook for Geron FY2028 Earnings

Key Points

• Wedbush analysts have revised their earnings estimate for Geron Corporation to $0.84 per share for FY2028, down from a previous forecast of $0.86.
• Despite posting quarterly revenue of $49.04 million, Geron's net margin remains negative at 53.52%, reflecting ongoing financial challenges.
• Several brokerages, including Scotiabank, have downgraded Geron's stock rating and significantly decreased their target prices, indicating a negative outlook from market analysts.

Geron Corporation (NASDAQ:GERN - Free Report) - Equities research analysts at Wedbush cut their FY2028 earnings estimates for Geron in a note issued to investors on Wednesday, August 6th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will post earnings per share of $0.84 for the year, down from their previous forecast of $0.86. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron's FY2029 earnings at $1.01 EPS.

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. Geron had a negative net margin of 53.52% and a negative return on equity of 31.37%. The business had revenue of $49.04 million during the quarter, compared to analyst estimates of $47.30 million. During the same quarter last year, the business earned ($0.10) earnings per share. Geron's quarterly revenue was up 5455.6% compared to the same quarter last year.

Several other brokerages also recently weighed in on GERN. Scotiabank downgraded shares of Geron from a "sector outperform" rating to a "sector perform" rating and reduced their target price for the company from $4.00 to $1.50 in a research note on Thursday, May 8th. The Goldman Sachs Group started coverage on shares of Geron in a research note on Thursday, July 10th. They issued a "sell" rating and a $1.00 target price on the stock. One investment analyst has rated the stock with a sell rating, three have given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $4.19.

Geron Price Performance

GERN stock opened at $1.28 on Monday. Geron has a 52 week low of $1.09 and a 52 week high of $4.84. The company has a quick ratio of 6.79, a current ratio of 7.87 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $1.39 and a two-hundred day simple moving average of $1.65. The firm has a market capitalization of $816.67 million, a P/E ratio of -9.85 and a beta of 0.73.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new position in Geron in the 4th quarter worth about $5,143,000. Ameriprise Financial Inc. increased its stake in Geron by 8.8% in the 4th quarter. Ameriprise Financial Inc. now owns 3,064,458 shares of the biopharmaceutical company's stock worth $10,845,000 after buying an additional 247,018 shares during the period. Raymond James Financial Inc. purchased a new position in Geron in the 4th quarter worth about $247,000. Stifel Financial Corp increased its stake in Geron by 29.9% in the 4th quarter. Stifel Financial Corp now owns 61,658 shares of the biopharmaceutical company's stock worth $218,000 after buying an additional 14,181 shares during the period. Finally, Bank of Montreal Can increased its stake in Geron by 38.9% in the 4th quarter. Bank of Montreal Can now owns 33,147 shares of the biopharmaceutical company's stock worth $117,000 after buying an additional 9,277 shares during the period. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.